Skip to main content

Search Videos and More

Showing 25 - 36 of 50 results

Previous| 1... 2 | 3 | 4 ...5 |Next

What should the ideal target LDL-C be in the Type 2 diabetes population? And what is the advantage of the treat-to-target strategy employed in ODYSSEY Outcomes and what did we learn about associated, all-cause mortality with alirocumab in that trial?

What should the ideal target LDL-C be in the Type 2 diabetes population? And what is the advantage of the treat-to-target strategy employed in ODYSSEY Outcomes and what did we learn about associated, all-cause mortality with alirocumab in that trial?

Although 70 mg/dL is the target threshold identified by both ESC and AHA, should the interventionalist, in a patient who has just undergone a PCI and has an LDL-C of 69 mg/dL, be considered adequately CV risk-mitigated?

Although 70 mg/dL is the target threshold identified by both ESC and AHA, should the interventionalist, in a patient who has just undergone a PCI and has an LDL-C of 69 mg/dL, be considered adequately CV risk-mitigated?

How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

Can you discuss the reductions in MACE events reported in the PCSK9 outcome trials and how they shape the benefit/safety equation for the use of alirocumab and evolocumab in high-risk patients, including diabetics, for secondary prevention of ASCVD?

Can you discuss the reductions in MACE events reported in the PCSK9 outcome trials and how they shape the benefit/safety equation for the use of alirocumab and evolocumab in high-risk patients, including diabetics, for secondary prevention of ASCVD?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

Can you help us de-convolute what is more important, (a) the absolute level of LDL-C level attained among patients in the ODYSSEY Outcomes Trial, or (b) the delta, i.e. the relative change from baseline LDL-C level at time of entry into the trial?

Can you help us de-convolute what is more important, (a) the absolute level of LDL-C level attained among patients in the ODYSSEY Outcomes Trial, or (b) the delta, i.e. the relative change from baseline LDL-C level at time of entry into the trial?

Showing 25 - 36 of 50 results

Previous| 1... 2 | 3 | 4 ...5 |Next